Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“DB06 analysis suggests a larger PFS benefit (Δ 7.5 mo) with T-DXd in patients with shorter time on prior CDK4/6i (ie aggressive tumors).
Smaller benefit (Δ 4.7 mo) in patients with >1 year on prior CDK4/6i. Helpful to inform the choice of 1L cape vs T-DXd.”
Title: Trastuzumab deruxtecan in hormone receptor–positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
Authors: G. Curigliano, X. Hu, R. Dent, K. Yonemori, C.H. Barrios, J.-Y. Pierga, F. Puglisi, J.-M. Ferrero, K.H. Jung, N.A. Bagegni, J. Collignon, M. Gil-Gil, X. Wu, A. Andrzejuk-Ćwik, M. Schwaederle, S. Anand, A. Bardia
Read the Full Article.
Other articles featuring Paolo Tarantino.
